Endologix today announced that it has completed its acquisition of PQ Bypass for an undisclosed amount.
PQ Bypass makes the Detour platform that is designed for percutaneous femoral-popliteal bypass — providing a large lumen, endograft bypass to treat abdominal aortic aneurysm. FDA has designated Detour as a breakthrough device.
The Detour System has the company’s Torus stent graft and the PQ Crossing Device. It is currently being studied in a U.S. and European clinical trial.
“The acquisition of PQ Bypass is a seminal moment in Endologix’s history, building upon our leadership in the treatment of abdominal aortic aneurysm to champion disruptive technologies for the treatment of vascular disease,” Endologix CEO Richard Mott said in a news release. “We intend to actively pursue new and innovative vascular technologies that are clinically relevant to surgeons, hospitals and patients, with a commitment to world-class medical education, clinical research and excellent procedural outcomes.”
Endologix currently makes devices to treat a wide spectrum of vascular disease from abdominal aortic aneurysms to lower limb peripheral vascular disease.